A Phase 2a, Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
- Funded by National Medical Research Council Singapore
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
National Medical Research Council SingaporePrincipal Investigator
Jenny LowResearch Location
SingaporeLead Research Institution
SHHQResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Phase 2 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase II
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified